Mikafungin Pharmazac (Micafungin)

Micafungin, the active ingredient in Mikafungin Pharmazac, is an echinocandin presented as an intravenous formulation for infusion use. It is indicated for the treatment of invasive fungal infections such as candidiasis in adult and pediatric patients with compromised immune systems.

GNH USA supplies Mikafungin Pharmazac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for critical care medicines, ensuring timely delivery to meet patient needs.

Micafungin is an echinocandin antifungal used to treat invasive Candida infections.

- Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: eradication of Candida infection of the esophagus. - Candida peritonitis: management of intra‑abdominal Candida infection. - Febrile neutropenia: prophylaxis against invasive fungal disease in neutropenic patients.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Chills: shaking sensations often accompanying fever. - Nausea: feeling of stomach upset. - Vomiting: expulsion of stomach contents. - Elevated liver enzymes: mild hepatic enzyme rise. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Severe hypotension: marked drop in blood pressure. - Renal impairment: acute kidney injury. - Stevens‑Johnson syndrome: severe skin and mucosal reaction. - Cytopenias: significant reduction in blood cell counts.

When using Micafungin, clinicians should observe several safety measures.

- Renal function: assess baseline and monitor during therapy. - Hepatic function: monitor liver enzymes before and during treatment. - Drug interactions: review concomitant medications for potential effects on micafungin levels. - Pregnancy and lactation: use only if the expected benefit justifies potential risk. - Infusion reactions: monitor the patient during administration for signs of hypersensitivity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - Cyclosporine: may increase micafungin plasma concentrations. - Rifampin: may markedly reduce micafungin exposure. - Carbamazepine: may lower micafungin levels, reducing efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): additive risk of hepatotoxicity. - Statins: monitor for myopathy when co‑administered. - Warfarin: observe INR values for potential anticoagulant effect changes.